NCT00966563 - Mangafodipir as an Adjunct to Percutaneous Coronary Intervention | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

May 31, 2013

Study Completion Date

July 31, 2013

Conditions

Myocardial Infarction

Interventions

DRUG

Mangafodipir

Administered dose: 2 µmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an intravenous (iv.) infusion over 2-5 min prior to reopening of occluded coronary artery during PCI

DRUG

Placebo

Trial Locations (1)

551 85

Department of Internal Medicine, County Hospital Ryhov, Jönköping